Results 141 to 150 of about 73,963 (300)

Successful Use of Bimekizumab in Refractory Acute Generalised Exanthematous Pustulosis Triggered by Amoxicillin‐Clavulanate

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Acute generalised exanthematous pustulosis (AGEP) is a rare, acute neutrophilic dermatosis most commonly triggered by drugs, which typically resolves within 2 weeks following withdrawal of the causative agent. Topical and systemic corticosteroids remain the standard treatment.
Alexandra Junge   +5 more
wiley   +1 more source

Characteristics and Clinical Outcomes of Patients With Hidradenitis Suppurativa (HS) Treated With Bimekizumab: A Canadian Retrospective Chart Review

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Hidradenitis suppurativa (HS) is a chronic, recurrent inflammatory skin disease characterised by painful nodules, abscesses, and draining and non‐draining tunnels. Currently, there are two biologics approved in Canada for the treatment of moderate‐to‐severe HS, adalimumab (anti‐TNF) and secukinumab (anti‐IL‐17A).
Irina Turchin   +4 more
wiley   +1 more source

Juvenile Mycosis Fungoides: A Multicenter Retrospective Italian Study

open access: yesJEADV Clinical Practice, EarlyView.
This multicenter retrospective study included 29 juvenile mycosis fungoides (JMF) patients from five Italian centres with confirmed histopathological diagnosis. most often presents with hypopigmented/classic variants and CD8+ phenotype. Early‐onset cases ( < 14 years) show better long‐term outcomes.
Andrea Michelerio   +8 more
wiley   +1 more source

Skin of Color Representation in Hidradenitis Suppurativa Textbooks

open access: yes
JEADV Clinical Practice, EarlyView.
Oswin Chang, Jincheng Shi
wiley   +1 more source

Home - About - Disclaimer - Privacy